Pomerantz Law Firm Highlights Class Action Against Corcept Therapeutics Over Potential Securities Fraud

Investor Alert: Class Action Against Corcept Therapeutics

Pomerantz LLP, renowned for its expertise in securities class actions, has officially filed a class action lawsuit against Corcept Therapeutics Incorporated. This alert is significant for investors who may have incurred losses associated with their investments in Corcept, traded on NASDAQ under the symbol CORT.

As underscored by the law firm, investors are encouraged to reach out to Danielle Peyton for further details. Interested parties should provide their contact information and the number of shares purchased to facilitate the process. This lawsuit centers around allegations that Corcept and several of its officers engaged in securities fraud and other unlawful business practices.

The deadline for investors to request the Court to appoint them as Lead Plaintiff in this case is April 21, 2026. For reference, the original complaint is accessible at Pomerantz Law Firm.

Background of the Case

The impetus for this lawsuit stems from a December 31, 2025 announcement by Corcept Therapeutics, revealing that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) in response to their New Drug Application for relacorilant, intended as a treatment for hypertension secondary to hypercortisolism. This letter indicated that the FDA could not arrive at a favorable benefit-risk assessment without additional evidence of the drug’s effectiveness from Corcept.

Following this distressing news, Corcept's stock price took a substantial hit, plummeting by $35.40 per share, translating to a staggering 50.4% decrease, which left the stock closing at $34.80 per share. The sharp decline prompted the law firm to act on behalf of affected investors, emphasizing that those financially impacted should consider joining the class action to seek potential remedies for their losses.

Pomerantz LLP, established by the historic attorney Abraham L. Pomerantz, is recognized as a leader in corporate and securities litigation. With over 85 years of experience, the firm has consistently fought for the rights of securities fraud victims, securing significant settlements and recoveries for class members over the years. Their reputation underscores the trustworthiness of this information, making it crucial for investors to consider their position.

How to Participate

Investors who have lost money due to their investment in Corcept Therapeutics during the class period should act quickly. It is advised that they take advantage of the opportunity to submit their information to become involved in the lawsuit. Direct communication with Pomerantz LLP can provide investors with the necessary guidance and support as they navigate this legal process.

This situation serves as a reminder of the volatility inherent in stock investments and the importance of due diligence. As always, staying informed and proactive in addressing potential concerns is key to safeguarding financial interests.

For more detailed information, investors can contact Pomerantz LLP through the provided channels or visit their website. Furthermore, investors are encouraged to keep abreast of any updates regarding this case as it progresses in court.

Remember, your participation could not only assist in recovering your losses but also promote accountability in corporate governance—a vital component of investor confidence in the market.